Haleon PLC Executes Share Buyback, Adjusts Share Capital

Haleon PLC ( (GB:HLN) ) just unveiled an update.

Haleon PLC announced the purchase and cancellation of 966,880 ordinary shares as part of its share buyback program. This transaction affects the company’s share capital, reducing the number of shares with voting rights to 8,992,482,913, which stakeholders can use to assess their interests under regulatory guidelines.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.

Haleon PLC’s overall stock score is driven by its strong financial performance and positive earnings outlook. However, overvaluation concerns and mixed technical indicators temper the score. The company’s proactive capital management through share buybacks further supports its market standing.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a portfolio that includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The company is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.

Average Trading Volume: 27,210,217

Technical Sentiment Signal: Buy

Current Market Cap: £35.62B

For a thorough assessment of HLN stock, go to TipRanks’ Stock Analysis page.